Rein Therapeutics
RNTX
Rein Therapeutics (RNTX) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.21
- EPS estimate
- −$0.24
- EPS surprise
- +12.50%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Nov 14, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 14, 2025 | −$0.24 | −$0.21 | +12.50% | $0.00 | SEC |
| Q2 2025 | Aug 14, 2025 | −$0.22 | −$0.28 | −27.27% | $0.00 | SEC |
| Q1 2025 | May 15, 2025 | −$0.21 | −$0.25 | −19.05% | $0.00 | SEC |
| Q4 2024 | Apr 7, 2025 | −$0.30 | −$1.89 | −530.00% | $0.00 | SEC |
| Q3 2024 | Nov 14, 2024 | −$0.25 | −$0.27 | −10.20% | $0.00 | SEC |
| Q2 2024 | Aug 14, 2024 | −$0.23 | −$0.45 | −99.47% | $0.00 | SEC |
| Q1 2024 | May 15, 2024 | −$0.14 | −$0.86 | −514.29% | $0.00 | SEC |
| Q4 2023 | Apr 15, 2024 | −$0.16 | −$1.54 | −840.75% | $0.00 | SEC |
| Q3 2023 | Oct 13, 2023 | −$0.20 | −$0.40 | −100.00% | $0.00 | SEC |
| Q3 2022 | Nov 1, 2022 | −$1.65 | −$1.40 | +15.15% | $0.00 | — |
| Q2 2022 | Aug 15, 2022 | −$1.70 | −$1.80 | −5.88% | $0.00 | — |
| Q1 2022 | May 5, 2022 | −$1.53 | −$1.80 | −17.39% | $0.00 | — |
| Q4 2021 | Mar 28, 2022 | −$1.60 | −$1.60 | +0.00% | $0.00 | — |
| Q3 2021 | Nov 12, 2021 | −$1.40 | −$1.40 | +0.00% | $0.00 | — |
| Q2 2021 | Aug 11, 2021 | −$1.47 | −$1.20 | +18.18% | $0.00 | — |
| Q1 2021 | May 11, 2021 | −$1.35 | −$1.60 | −18.52% | $0.00 | — |
| Q4 2020 | Mar 24, 2021 | −$2.55 | −$2.40 | +5.83% | $0.00 | — |
| Q3 2020 | Nov 12, 2020 | −$2.50 | −$2.60 | −4.00% | $0.00 | — |
| Q2 2020 | Aug 5, 2020 | −$3.75 | −$2.80 | +25.33% | $0.00 | — |
| Q1 2020 | May 11, 2020 | −$4.05 | −$4.80 | −18.52% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Rein Therapeutics (RNTX) last report earnings?
Rein Therapeutics last reported on Nov 14, 2025, covering fiscal Q3 2025.
Did RNTX beat earnings estimates?
Yes. Rein Therapeutics reported EPS of −$0.21 for Q3 2025 against a −$0.24 estimate — a 12.50% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.